In nonsevere hemophilia A patients the presence of an inhibitor may exacerbate the bleeding phenotype dramatically. There are very limited data on the optimal therapeutic approach to eradicate inhibitors in these patients.
ABSTRACT Background
In nonsevere hemophilia A patients the presence of an inhibitor may exacerbate the bleeding phenotype dramatically. There are very limited data on the optimal therapeutic approach to eradicate inhibitors in these patients.
Objective
We aimed to describe inhibitor eradication treatment in a large cohort of unselected nonsevere hemophilia A patients with inhibitors.
Patients/Methods
We included 101 inhibitor patients from a source population of 2,709 nonsevere hemophilia A patients (factor VIII, 2-40 IU dL -1 ), treated in Europe and Australia (median age 37 years; interquartile range [IQR], 15-60; median peak titer, 7 BU mL -1 , IQR, .
Results
In the majority of the patients (71%; 72/101) the inhibitor disappeared; either spontaneously (70%; 51/73) or after eradication treatment (75%; 21/28). Eradication treatment strategies varied widely, including both immune tolerance induction and immunosuppression. Sustained success (no inhibitor after rechallenge with factor VIII concentrate) was achieved in 69% (36/52) of the patients. In high titer inhibitor patients sustained success was associated with eradication treatment (relative risk, 2.3; 95% confidence interval, 1.3-4.3), compared to no eradication treatment.
Conclusions
In this cohort of nonsevere hemophilia A patients with inhibitors, patients did seem to benefit from eradication treatment. Inhibitor eradication in nonsevere hemophilia A patients requires a bespoke approach, as one single approach is unlikely to be appropriate for all.
INTRODUCTION
Hemophilia A is an X-linked bleeding disorder caused by deficiency of coagulation factor VIII. Factor VIII concentrate is administered intravenously to treat or prevent bleeding. 1 The development of neutralizing factor VIII antibodies (inhibitors) is the most challenging and severe complication of clotting factor replacement in hemophilia A. In severe hemophilia A this complication mainly occurs during childhood, however patients with nonsevere hemophilia A (factor VIII activity [FVIII:C], 2-40 IU dL -1 ) are at a lifelong risk for inhibitor development. 2 Prior to inhibitor occurrence, patients with mild hemophilia A would normally only experience incidental bleeding episodes elicited by trauma. 1 The inhibitor may aggravate the bleeding phenotype dramatically -resulting in more frequent spontaneous bleeds -if it reduces the endogenous factor VIII plasma levels below 1 IU dL -1 . 3;4 Subsequent clinical decisions become more challenging, particularly in the setting of relevant co-morbidities such as cardiovascular disease. Expensive factor VIII bypassing agents (FEIBA [Baxter] or recombinant FVIIa [Novoseven, Novonordisk]) are administered to gain adequate hemostasis with varying efficacy in achieving a satisfactory state of hemostasis, resulting in increased morbidity.
Although previously the incidence of inhibitor development in nonsevere hemophilia A patients was estimated to be between 3-13%, recently certain factor VIII gene (F8) mutations have been identified that are associated with higher inhibitor rates. 2;3;4 For some F8 genotypes the inhibitor incidence approximates the rates observed in severe hemophilia A. Moreover, inhibitor incidences in nonsevere hemophilia patients progressively increase with cumulative number of factor VIII exposure days apparently without reaching a plateau, which contrasts with the observations in patients with severe hemophilia A. Inhibitor risk after 20, 50 and 100 exposure days is estimated at 3.5% (95% confidence interval [CI], 2.1-4. 9), 6.7% (CI, 4.5-8. 9) and 13.3% (CI, 9.6-17.0), respectively. 2 Since inhibitor development in nonsevere hemophilia A is a substantial and relevant clinical problem, there is a clinical imperative to know more about treatment regimens aimed at inhibitor eradication in nonsevere hemophilia A.
Our current knowledge on inhibitor eradication treatment is largely based on studies and clinical experience in severe hemophilia A patients with inhibitors. 5 A common approach to inhibitor eradication in severe hemophilia A is Immune Tolerance Induction (ITI). This was first described in the 1970s and in the past decades several treatment protocols have been developed. [6] [7] [8] [9] [10] [11] These protocols consist of the administration of frequent high doses factor VIII concentrate with the aim of gaining tolerance to the factor VIII protein. 12 Less commonly, medication such as prednisolone, cyclophosphamide or anti-CD20 (Rituximab ® ) are administered to suppress the immune response. 13;14;9 There are very limited data on the optimal therapeutic approach to eradicate inhibitors in nonsevere hemophilia A patients. 15 In these patients, losing and re-achieving tolerance to therapeutic factor VIII concentrate may be subject to different immunological mechanisms compared to patients with severe hemophilia A. 16 As patients with nonsevere hemophilia A do have circulating endogenous factor VIII, in contrast to patients with severe hemophilia A, the allogeneic mismatch between endogenous and the exogenous therapeutic factor VIII is less than in severe hemophilia A. These nonsevere hemophilia A patients have continuous exposure to their endogenous factor VIII, which in most cases will only differ to infused wild type factor VIII by a single amino acid as a result of a F8 missense mutation. If an inhibitor occurs, the factor VIII antibody is initially formed against the infused therapeutic (wild type) factor VIII, but can then cross-react with the endogenous factor VIII. In contrast to severe hemophilia A, inhibitors arising in nonsevere hemophilia A often have complex kinetics and a bleeding phenotype similar to acquired hemophilia A. Consequently, immunosuppressive strategies are reported more frequently to eradicate the inhibitor than in severe hemophilia A patients. 3 Anecdotally, there is less sensitivity about exposing patients to immunosuppressive therapy since these nonsevere inhibitor patients are often adult rather than pediatric patients.
Therefore, nonsevere hemophilia A patients may require a different approach than the traditional immune tolerance induction applied in severe hemophilia A. However, currently there is insufficient evidence to reach a consensus on the optimal therapeutic approach for inhibitor eradication in nonsevere hemophilia A.
We studied therapeutic approaches that have been used for inhibitor eradication and their resultant outcome in the largest, unselected international cohort of patients with nonsevere hemophilia A with inhibitors reported so far.
PATIENTS AND METHODS

Subjects and study design
In this cohort study we included all nonsevere hemophilia A patients (FVIII:C, 2-40 IU dL -1 ) who developed a clinically relevant inhibitor between 1980 and 2011 in one of the 34 participating centers of the INSIGHT study (investigators and centers are listed in the appendix): an international, multicenter cohort study that included all nonsevere hemophilia A patients who received at least one exposure to factor VIII concentrate during the observation period. The institutional review boards of all participating centres approved the study. The inhibitor patients were located in 29 European centres and Australia.
For the present satellite study we collected data on inhibitor titers, inhibitor eradication treatment and outcome. Detailed characteristics of the source population (genotype and inhibitor risk) are described elsewhere. 2
Definitions and features of variables
Patients were tested for inhibitors according to local practice and the results of all inhibitor tests were reviewed to confirm the inhibitor status of the patients. Inhibitory factor VIII antibodies were quantified at each local laboratory by the original Bethesda method or the Nijmegen modified assay from the nineties onwards. 17;18 Protocols of the inhibitor assay of all participating centers are available from the corresponding author. 2 Inhibitor titers were expressed in Bethesda Units per milliliter (BU mL -1 ). A clinically relevant inhibitor was defined as having at least two consecutive positive Bethesda inhibitor assay titers of ≥ 1.0 BU mL -1 . Patients with inhibitor titers between 0.6-1.0 BU mL -1 had to fulfill one of the following two criteria to be classified as having a clinically relevant inhibitor: 1.) a decrease in endogenous factor VIII plasma level to at least 50% of the baseline level, or 2.) a reduced half-life of less than six hours after factor VIII concentrate administration. Patients who were not tested for inhibitors during the follow-up period and who had no clinical features of inhibitor development (e.g. increased bleeding tendency) were classified as negative for inhibitors.
A negative inhibitor titer was defined as a Bethesda inhibitor assay of < 0.6 BU mL -1 on two consecutive assays. Historical peak titer was defined as the highest inhibitor titer available. A high titer inhibitor was defined as a historical peak titer > 5.0 BU mL -1 and a low titer inhibitor was defined as a historical peak titer of 0.6-5.0 BU mL -1 . Pre-ITI titer (pre-titer) was defined as the most recent inhibitor titer available before the start of inhibitor eradication therapy. We defined inhibitor eradication therapy as any treatment with the objective to eradicate the inhibitor. ITI was defined as regular treatment with factor VIII concentrate without adjunctive medication.
Inhibitor disappearance was defined as: a) a baseline FVIII:C level similar to the pre-inhibitor FVIII:C level and b) at least two consecutive Bethesda inhibitor assays of < 0.6 BU mL -1 . Inhibitor disappearance was referred to as "spontaneous" in the absence of eradication treatment. Sustained success was defined as lack of anamnestic response (i.e. a persistent negative inhibitor titer) upon rechallenge with factor VIII concentrate after disappearance of the inhibitor. Relapse of an inhibitor was defined as the recurrence of the inhibitor upon rechallenge with factor VIII concentrate after prior inhibitor disappearance.
We classified all centers included in this study as a small or large hemophilia treatment center using an arbitrarily chosen cut-off value of 30 patients; ' small' being hemophilia treatment centers caring for ≤ 30 nonsevere hemophilia A patients that had ever been treated with factor VIII concentrates (n = 7) and 'large' hemophilia treatment centers caring for > 30 nonsevere hemophilia A patients ever treated with factor VIII concentrates (n = 23).
Statistical analysis
Continuous variables were expressed as median values and interquartile ranges (IQR). Categorical variables were expressed as frequencies and percentage values and compared by χ 2 or Fisher' s exact test, as appropriate. The relative risks (RR) and 95% confidence intervals (CI) were calculated using a 2x2 table to compare treatment and outcome between groups. All analyses were performed with SPSS software (IBM Corp. 
RESULTS
Patient characteristics
We identified 107 nonsevere hemophilia A patients with an inhibitor within the total cohort of 2,709 consecutively treated patients that were exposed to clotting factor concentrates between 1980 and 2011. Data on inhibitor eradication treatment and outcome were available in 101 patients ( Figure 1 ). The baseline characteristics are shown in Table 1 and Table 2 . A high titer inhibitor was present in 56 patients, 45 patients had a low titer inhibitor. The baseline FVIII:C level was decreased at inhibitor detection in 58 patients (57%) with a median FVIII:C level at first positive inhibitor test of 1.4 IU dL -1 (IQR, 1.0-3.2). In 29 patients (29%) the FVIII:C level was decreased ≤ 1 IU dL -1 .
Inhibitor eradication treatment
Eradication treatment was administered in 28 patients (28%). Patients, in whom the inhibitor reduced the baseline FVIII:C level to a FVIII:C level of ≤ 1 IU dL -1 , were treated more often with eradication therapy than the others (43% vs. 17%, unadjusted RR, 2.6; CI 1.3-5.3). In small hemophilia treatment centers eradication treatment was more frequently prescribed than in larger hemophilia treatment centers (53% vs. 22%; unadjusted RR, 2.3; CI, 1.2-4.2).
The eradication treatment consisted of ITI exclusively in 16 patients, five patients were treated with immunosuppressive medication exclusively and the other seven received a combination of ITI and immunosuppressive medication. The characteristics of the treatment in these patients are specified in Table 3 . In the 23 patients receiving ITI (either exclusively or concomitant with immunosuppressive medication), ten patients were treated with recombinant factor VIII concentrates, 11 patients with plasma derived factor VIII concentrates and in two patients the type of factor VIII concentrate used for ITI was unknown.
The following immunosuppressive drugs were used: prednisone (n = 8), cyclophosphamide (n = 7) and rituximab (n = 4). For the patients that received inhibitor eradication treatment, the median time between first positive inhibitor test and inhibitor disappearance was 10 months (IQR, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and for the patients that did not receive eradication treatment 18 months (IQR, . The median time between start of eradication therapy and inhibitor disappearance was seven months (IQR,3-15) and the median time of follow-up after inhibitor disappearance was 91 months (IQR, 48-161).
Eradication treatment was not offered before 1990 to the four patients that developed an inhibitor between 1980-1989. In the 97 patients that developed an inhibitor between 1990-2011, 28 (29%) received eradication treatment. Age at inhibitor development was lower in patients that were treated with ITI exclusively (median age, 13 years; IQR, 7-33) than in the patients that did not receive eradication treatment (median age, 42 years; IQR, 19-62). Treatment with exclusively immunosuppressive medication was given to older patients (median age, 69 years; IQR, 50-79) in comparison to patients receiving other eradication treatment. Table 3 . at time of inclusion ITI duration was 9 months but ITI was still ongoing. ¶ at time of inclusion ITI duration was 11 months but ITI was still ongoing. Table 3 .
Continued
Outcome of inhibitor eradication treatment
The outcome of eradication management is presented in Table 4a and 4b. Eradication treatment was administered in 28 patients (28%) and the inhibitor disappeared after treatment in 21 patients. Of these 21 patients, 17 were rechallenged with factor VIII concentrate. The majority (88%; 15/17) had sustained success after inhibitor eradication as they remained inhibitor free after rechallenge with factor VIII concentrates. The other two rechallenged patients had a relapse of the inhibitor. The remaining 73 inhibitor patients did not receive any inhibitor eradication treatment. In 51 (71%) of them the inhibitor disappeared spontaneously. Of these 51 patients, rechallenge with factor VIII concentrate occurred in 35 patients. Sustained success was observed in 21 patients (60%; 21/35). The use of eradication treatment was associated with sustained success (unadjusted RR, 1.5; CI, 1.1-2.0) when compared to no eradication treatment.
The number of patients needing treatment for bleeding episodes (bypassing agents) during the inhibitor episode was similar between the group that received eradication treatment and the group that did not receive eradication treatment (85% vs. 90%; unadjusted RR, 0.88; CI, 0.53-1.28). Treatment with bypassing agents (FEIBA or recombinant FVIIa) after inhibitor disappearance occurred in nine of the 72 patients.
Titer and outcome
In the patients with a low titer inhibitor, inhibitor disappearance was more frequent than in patients with a high titer inhibitor (84% vs. 62%; unadjusted RR, 1.4; CI, 1.1-1.7). However, there was no clear difference in sustained success between these groups (73% vs. 64%; unadjusted RR, 1.2; CI, 0.8-1.7). In all 11 patients with low titer inhibitors that received eradication treatment the inhibitor disappeared and nine patients were rechallenged with factor VIII concentrate. Sustained success was attained in seven (78%; 7/9) of these patients. In the 34 low titer patients that did not receive eradication treatment, the inhibitor disappeared in 27 patients and 21 were rechallenged. Fifteen (71%; 15/21) of them demonstrated sustained success. Sustained success was not associated with eradication treatment in low titer patients (unadjusted RR, 1.1; CI, 0.7-1.7).
In ten (59%) of the 17 high titer patients that received eradication treatment the inhibitor initially disappeared; eight patients were rechallenged. Of the 39 high titer patients without eradication therapy, the inhibitor disappeared in 25 patients and 14 were rechallenged. Sustained success was attained in all eight patients (100%) that were rechallenged after eradication treatment, compared to six (43%; 6/14) patients without eradication that were rechallenged (unadjusted RR, 2.3; CI, 1.3-4.3). The effect of eradication therapy did not differ in the subgroup of patients with a decrease of their FVIII:C level to below 1 IU dL -1 in comparison to patients that did not have a decrease of their FVIII:C below 1 IU dL -1 . 
DISCUSSION
This unique and unprecedented large cohort of 101 nonsevere hemophilia A patients with inhibiting antibodies provides an insight into inhibitor management strategies in Europe and Australia. In half of the patients (51/73; 70%) the inhibitor disappeared spontaneously, without eradication treatment. In the majority of the remaining 28 patients that did receive eradication treatment the inhibitor also disappeared (n = 21; 75%), in these patients the treatment strategy varied widely. Both high titer and low titer inhibitor patients seemed to benefit from eradication treatment, however in the low titer patients sustained success without eradication treatment was also very likely.
The results of this study should be interpreted with care. Only patients with a clinically relevant inhibitor were classified to be positive for an inhibitor in our analysis (see Patients and methods). Patients who were not tested for inhibitors during the follow-up period and who had no clinical features of inhibitor development (e.g. increased bleeding tendency) were classified as negative for inhibitors. This may have underestimated inhibitor occurrence resulting in a conservative assessment of inhibitor outcome, as the mildest cases, with expectedly the highest success rates, may have not entered the study. Although the inhibitor disappearance rate was similar in patients treated or observed (75% vs. 71%) this does not mean that these strategies are equally effective, since patients were not randomized. It is likely that the most severe patients are treated with inhibitor eradication, and therefore the effect of this strategy may be underestimated in our study. Moreover, the heterogeneity of the patients in characteristics and in management, due to national differences and the large time span of the study, preclude firm conclusions on the effectiveness of eradication treatment used in these patients.
Over the past decades many different definitions of immune tolerance have been used. Our definition of successful immune tolerance induction differs from the more frequently used definition that includes restoration of normal pharmacokinetics of FVIII:C after a 3-day washout period, together with a negative inhibitor titer. 12 Since we observed that in the majority of the participating hemophilia treatment centers regular data on FVIII:C half-life and recovery measurements were not available, we did not use this for classification.
Inhibiting antibodies can become quiescent in the absence of further challenges with factor VIII concentrate. We believe true tolerance is present when no anamnestic response occurs after rechallenge with factor VIII concentrate. Therefore we have used this definition in our study for "sustained success". When rechallenge does not occur sustained success cannot be evaluated. In this case disappearance of the inhibitor might be due to an extinguished immune response in absence of the antigen and therefore evaluation of the outcome of eradication treatment cannot be established.
The median time between first positive inhibitor test and inhibitor disappearance seems nearly twice as long in the patients without eradication treatment (18 months) compared to the patients with eradication treatment (10 months). Presumably, the timing of inhibitor testing will have been ad hoc in patients without eradication treatment and patients with eradication treatment had more structured inhibitor screening. This difference in testing hampers a valid comparison between these two groups for time to inhibitor disappearance.
Also, significant time intervals between exposure to factor VIII concentrate and inhibitor screening might lead to oversight of inhibitor relapse after minor exposure. Inhibitor testing does not always occur shortly after a patient is rechallenged with factor VIII concentrate, especially when there are no clinical signs of inhibitor development. When the time interval between rechallenge and inhibitor testing is too long, a low titer relapsing inhibitor might be missed.
In our cohort, sustained success was attained in 100% (8/8) of the high titer and in 77% (7/9) of the low titer patients receiving eradication treatment. Due to the very small numbers in these groups we have to interpret the findings with great care. However, it is worth noting that eradication treatment failed in two low titer patients. Yet the dose of factor VIII for ITI in those two patients was relatively low. Other patients treated with similar dosages received immunosuppressive medication concurrently.
Rechallenging a patient with a low titer inhibitor with factor VIII concentrate could elicit an anamnestic response and a high titer inhibitor may result. There is a substantial risk of severe complications when the inhibitor relapses at high titre after rechallenge with factor VIII concentrate. Therefore the decision to rechallenge a patient with factor VIII concentrate after spontaneous disappearance of an inhibitor must be taken with care. These concerns may prevent clinicians from rechallenging an inhibitor patient with factor VIII concentrate. This may partly explain why 21 of the 73 patients in whom the inhibitor disappeared in our study were never rechallenged with factor VIII concentrate. Importantly, this potentially reflects compromises in the medical management of these patients. Patients that were rechallenged with factor VIII concentrate may consist of a subgroup with more favourable prognostic factors. In the analysis this may invoke bias, overestimating the occurrence of sustained success. It is important to note that the risk of relapse may also depend on the reason for rechallenge, e.g. minor spontaneous bleeding versus major surgery. This implies that a patient that has been rechallenged for a minor bleed cannot necessarily be treated safely with factor VIII concentrates for several days for a major surgery.
A recent study of Kempton and colleagues reported a better effect of rituximab on inhibitor eradication in 32 mild and moderate hemophilia A patients than ITI. 19 We could neither confirm nor deny this observation in our study as only four patients were treated with rituximab, and all of them received it in combination with immune tolerance induction.
Beside the treatment regimen and clinical determinants it is important to obtain more knowledge on the genetic determinants of the outcome of inhibitor eradication in nonsevere patients. Unfortunately, we could not analyze the effect of F8 genotype in our study as there were only four mutations that occurred in three or more subjects (i.e. Arg593Cys, Tyr2105Cys, Arg2150His and Trp2229Cys). For future studies addressing the determinants of successful inhibitor eradication in nonsevere hemophilia A it is important that uniform definitions of true tolerance are used that take the effect of rechallenge with factor VIII concentrates into account.
This observational study was designed to describe the therapeutic approaches that have been used to eradicate inhibitors in nonsevere hemophilia A patients. Due to the nature of this study we cannot formulate any treatment recommendations for nonsevere hemophilia A inhibitor patients yet. This study shows that some patients may benefit from eradication treatment; however one single approach is unlikely to be appropriate for all patients. Consequently, clinicians will need to continue to make these decisions on a case by case basis. Often the severe bleeding complications and related morbidity of the inhibitor seems to be the most important reason for clinicians to start eradication treatment.
Further research is needed to determine factors that can predict which nonsevere hemophilia A patients require treatment to eradicate their inhibitor. Recommendations should be based on patient and inhibitor characteristics, and may be different from the recommendations in severe hemophilia A patients. 20 Specifically for patients with nonsevere hemophilia there may be a role for desmopressin in preventing inhibitor development and/or relapse. 15 Since a fair proportion of the nonsevere hemophilia A patients can be effectively treated with desmopressin for bleeding episodes and minor surgery, this seems a feasible and safe objective for patients without cross-reacting inhibitors.
This study is an advance over registry-type and single institution studies and provides a solid summary of the overall outcome of both low and high titer inhibitors in nonsevere hemophilia A patients. With the stringent definitions that were employed, this study may provide input for prospective studies that aim to identify predictors for succesful inhibitor eradication. However, given that this data required collection over 31 years, this highlights the challenges in executing such studies in this rare patient group.
